Switzerland's Lonza has negotiated exclusive rights to an
expression system, used in the manufacture of therapeutic proteins,
that could be used to shorten the development time for its
customers' biologic products.
France's Nautilus Biotech says that it has achieved a key technical
milestone in a collaboration with Aventis Pasteur, designed to
improve the productivity of the latter's vaccine manufacturing
process.
Axon has licensed rights to Cellectricon's electroporation
technology to enhance the performance of its Axoporator products,
used to deliver DNA and other large molecules into cells.
GlaxoSmithKline has secured rights to a technology, developed in
partnership with US company Advaxis, could improve the
effectiveness of vaccine-based treatments for cancer.
The UK's Genetix, which makes gene and protein research equipment,
said it had received orders from leading pharmaceutical groups for
two of its new products.
Centocor forged a deal with Biolex in which the latter firm will
examine the feasibility of producing three therapeutic proteins
using a proprietary plant-based expression system
